MB-105 study (NCT06534060), a Phase 2, open-label, single-arm, multicenter clinical trial for patients with CD5-positive relapsed or refractory T-cell lymphoma (r/r TCL). The study uses a Simon two-stage design.
Baylor College of Medicine
Houston, Texas, United States, 77030 Map
Contact: Brandon Garner
Email: bjgarner@texaschildrens.org
Phone: 832-824-4594
Principal Investigator: LaQuisa Hill, MD
MD Anderson Cancer Center
Houston, TX 77030 Map
Contact: Christine Samuel
Email: csamuel@mdanderson.org
Phone: 713-745-7143
Principal Investigator: Swaminathan Iyer, MD
University of Iowa
Iowa City, Iowa 52242 Map
Contact: Gail Nelson
Email: gail-nelson@uiowa.edu
Phone: 319-678-7922
Principal Ivestigator: Eric Mou, MD
Massachusetts General Hospital
Boston, MA 02114 Map
Contact: Michael Rabinovich
Phone: 617-724-9190
Principal Investigatory: Salvia Jain, MD